drugset / Trial / NCT03054350

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03054350

Phase 2 Completed 60 enrolled Akebia Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Dialysis-dependent Chronic Kidney Disease (DD-CKD).

Timeline

Start
2016-12
Primary completion
2017-10-24
Completion
2018-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Vadadustat Small molecule Oral